Coronavirus vaccine: Covaxin to be at least 60% effective, says Bharat Biotech

Share

The trial in Britain and others around the world had already resumed.

AstraZeneca PLC (LON:AZN) is reportedly delivering the first batches of the vaccine developed with Oxford University to London hospitals as soon as next week. Older patients have been hardest hit by the pandemic, with the vast majority of deaths occurring in those over 60.

Immunogenicity blood tests, conducted on a subset of older participants, show similarity with data released in July this year that said the Oxford vaccine generated "robust immune responses" in a group of healthy adults, who were aged between 18 and 55.

UK Health Secretary Matt Hancock further fuelled optimism Monday, noting in an interview that once approved the "bulk" of the vaccine's rollout could occur in Britain before next summer.

A third European Union official said this bold goal could be achieved if the European Union reached supply deals with at least seven vaccine candidates.

The Oxford vaccine is seen as one of the most promising within that race, which in India is being trialled in partnership with the Serum Institute of India.

Congress in March sought to mandate free coronavirus vaccine coverage as part of a broader Covid-19 relief bill.

B.C. voter turnout down significantly, despite 1.8 million ballots cast
If you have not received your ballot in the mail, you have several options as follows to either vote or to get your ballot . The polls for the general election will be open from 6:30 a.m. - 7:30 p.m., Tuesday, Nov. 3.

"Although we're not developing the vaccines ourselves, it is a lot of work". A late-stage trial of the shot was restarted last week in the US after a temporary halt that followed a participant's illness in a separate United Kingdom study.

The EU Commission had earlier said vaccines will be limited "during the initial stages of deployment" but had never clarified how long the initial phase would last.

The Trump administration is preparing to announce this week that Medicare and Medicaid will cover the out-of-pocket costs of the future coronavirus vaccine to let older and at-risk Americans get the jab for free.

Besides, Bharat Biotech's COVAXIN, another indigenously developed vaccine candidate by Zydus Cadila Limited is also in Phase -2 of human clinical trials.

The ministry added that it had given a green light to some 26 clinical trials for Covid-19 treatments and vaccines as of Monday, by entities such as pharmaceutical companies Celltrion Inc and Genexine Inc, with seven completed and 19 ongoing.

Concerns have also been raised for when hospitals first receive vaccines for front-line staff.

Share